Axsome Therapeutics

Axsome Therapeutics shares are up 16% year‑to‑date as Q2 revenue rose 46% to $218.4 million, driven by Auvelity net sales of $180.3 million and a recent FDA label expansion for Alzheimer's agitation. The company is advancing multiple mid/late‑stage programs—including AXS‑12 under regulatory review and trials for AXS‑14 and AXS‑20—and projects peak sales above $16 billion. Wall Street price targets imply further upside, though clinical, regulatory and competitive risks could derail forecasts. » More on finance.yahoo.com

ClearBridge Small Cap Growth Strategy added Axsome Therapeutics as a new position, citing its commercial-stage CNS focus and the large opportunity for its key drug Auvelity after approval in major depressive disorder and recent expansion into Alzheimer’s disease agitation. Axsome closed July 23 at $241.53 with a $12.43 billion market cap and has gained 139.54% over the past 52 weeks. The strategy delivered strong absolute returns in Q2 2026 but lagged the Russell 2000 Growth due to underweights in high-beta AI names and mixed performance in some healthcare holdings. » More on finance.yahoo.com

Axsome Therapeutics has seen its market value double to $12.6 billion after FDA approval of Auvelity for Alzheimer’s agitation and strong uptake since launch. CEO Herriot Tabuteau forecasts the Auvelity franchise could reach $8 billion in peak sales and the company has expanded its sales force and filed additional drug applications, including for narcolepsy. Axsome reported $709 million revenue for the past 12 months, is pursuing multiple pipeline programs and projects sustained filings and growth through 2030. » More on forbes.com